Vinge has advised Impilo with regulatory advice on the establishment of Impilo Orphan Drugs, a so-called continuation fund. The continuation fund will have EUR 320m in commitments and will invest in Immedica, in which KKR recently became an owner alongside Impilo.
Impilo is a Nordic investment company specializing in investments within the pharmaceutical, medical technology, healthcare services and other health-related industries. Impilo holds a highly diversified portfolio of healthcare investments and manages approximately EUR 1 billion in capital, from leading Nordic and international investors.
Vinges team consisted of Nils Unckel, Anton Sjökvist and Viktoria Wnuk.
